Stable performance during Covid
In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony linac and regulatory clearances enhanced our product portfolio and strengthened our ability to deliver on our strategy of Precision Radiation Medicine.
Gustaf Salford
President and CEO
Second quarter
· Covid-19 continued to have a negative impact on Elekta's growth in the quarter
· Gross order intake amounted to
· Net sales were
· Gross margin amounted to 40.9 (41.0) percent
· EBITA increased by 39 percent to
· Earnings per share was
· Cash flow after continuous investments improved by
· Launch of a new linac solution, Harmony
First six months
· Gross order intake amounted to
· Net sales were
· Gross margin amounted to 43.2 (41.7) percent
· EBITA amounted to
· Earnings per share was
· Cash flow after continuous investments improved by
Significant events after the quarter
·
· Introduction of
to a single room.
[image]
[1] After continuous investments.
[2] Before / after dilution.
[3] Based on constant currency.
# # #
For further information, please contact:
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
Johan Adebäck, Acting CFO,
Tel: +46 70 873 33 21, e-mail: johan.adeback@elekta.com
Time zone: CET: Central European Time
This is information that
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in
https://news.cision.com/elekta/r/interim-report--may-october-2020-21,c3243789
https://mb.cision.com/Main/35/3243789/1340078.pdf
https://news.cision.com/elekta/i/group-summary,c2854056
(c) 2020 Cision. All rights reserved., source